Peptides for Weight Loss South Africa

GLP-1 receptor agonists like semaglutide have transformed obesity research over the last five years. In the STEP trials, weekly subcutaneous semaglutide produced an average ~15% reduction in body weight at 68 weeks versus ~2.4% on placebo, by slowing gastric emptying and reducing appetite via hypothalamic GLP-1 receptors. In South Africa, semaglutide is dispensed pharmaceutically as Ozempic and Wegovy, but research-grade material is the same molecule sold for laboratory study only.

Tirzepatide is a dual GIP/GLP-1 agonist; in SURMOUNT-1 the 15 mg weekly dose drove ~22.5% mean weight loss at 72 weeks — meaningfully greater than semaglutide. Retatrutide takes this further as a triple GIP/GLP-1/glucagon agonist currently in Phase 3, with Phase 2 data showing ~24% weight loss at 48 weeks. The added glucagon agonism is hypothesised to increase resting energy expenditure on top of appetite suppression.

MOTS-c sits in a different category: it is a 16-amino-acid mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity, and supports metabolic flexibility independent of the GLP-1 axis. It is typically researched alongside (not instead of) the incretin-class peptides above where the goal is body recomposition rather than weight on a scale alone.